Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 6/20 | 0.60 |
| ▸ | RXRA | P19793 | 12/20 | 0.56 |
| ▸ | RARA | P10276 | 5/20 | 0.44 |
| ▸ | RXRG | P48443 | 4/20 | 0.44 |
| ▸ | RXRB | P28702 | 4/20 | 0.44 |
| ▸ | RARB | P10826 | 5/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.43 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870417 | 1.00 | RARG (0.60) | RARGRXRARARARXRGRXRB | |
| SCHEMBL17049093 | 0.82 | RXRA (0.57) | RARGRXRARARARXRGRXRB | |
| SCHEMBL17049091 | 0.82 | RXRA (0.57) | RARGRXRARARARXRGRXRB | |
| SCHEMBL14785625 | 0.77 | RXRA (0.59) | RARGRXRARARARXRGRXRB | |
| SCHEMBL14785626 | 0.77 | RXRA (0.59) | RARGRXRARARARXRGRXRB | |
| SCHEMBL17049063 | 0.77 | RXRA (0.56) | RARGRXRARARARXRGRXRB | |
| SCHEMBL17049061 | 0.77 | RXRA (0.56) | RARGRXRARARARXRGRXRB | |
| SCHEMBL6822269 | 0.76 | RXRA (0.67) | RARGRXRARARARXRGRXRB | |
| SCHEMBL6032311 | 0.76 | RXRA (0.67) | RARGRXRARARARXRGRXRB | |
| SCHEMBL6874738 | 0.76 | RXRA (0.67) | RARGRXRARARARXRGRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | BERNARDON JEAN-MICHEL | 2003-07-17 | — | — | US | claimed |
| US-20030060491-A1 | Bicyclic aromatic compounds | BERNARDON JEAN-MICHEL (FR) | 2003-03-27 | — | — | US | claimed |
| EP-0832081-B1 | BICYCLIC-AROMATIC COMPOUNDS | GALDERMA RECH DERMATOLOGIQUE (FR) | 2003-01-29 | — | — | EP | claimed |
| US-10005741-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-05-24 | — | — | US | disclosed |
| US-9908856-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2015130973-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-09-03 | — | — | WO | disclosed |
| US-6825360-B1 | Bicyclic aromatic compounds | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-11-30 | — | — | US | disclosed |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | BERNARDON JEAN-MICHEL | 2003-07-17 | — | — | US | disclosed |
| US-20030060491-A1 | Bicyclic aromatic compounds | BERNARDON JEAN-MICHEL (FR) | 2003-03-27 | — | — | US | disclosed |
| US-6515021-B1 | Bicyclic aromatic compounds | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2003-02-04 | — | — | US | disclosed |
| US-6147255-A | TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH KERATINIZATION DISORDER WHICH HAS EFFECT ON DIFFERENTIATION AND ON PROLIFERATION | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060491-A1 | Bicyclic aromatic compounds | MITF, TYR, PAH | RARG 474/4885RXRA 196/4885RARA 451/4885 |
| US-20030135053-A1 | For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics | MITF, TYR, PAH | RARG 69/4885RXRA 55/4885RARA 52/4885 |
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | IAPP, PARK7, NLN | RARG 387/4885RXRA 674/4885RARA 631/4885 |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | IAPP, PARK7, NLN | RARG 387/4885RXRA 674/4885RARA 631/4885 |
| US-10005741-B2 | Therapeutic compounds | IAPP, PARK7, NLN | RARG 387/4885RXRA 674/4885RARA 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.